📅 2026 Update: Advances in Mesothelioma Treatment and Support

Since the original article was written, important advancements have occurred in the treatment of mesothelioma, particularly with the approval of new immunotherapy drugs. These updates provide more options for patients facing this challenging cancer. The earlier article continues further down the page, offering foundational information on mesothelioma and legal aspects related to asbestos exposure.

🩺 FDA Approvals for Immunotherapy

In September 2024, the FDA approved Keytruda® (pembrolizumab) for patients with unresectable advanced or metastatic pleural mesothelioma. This approval allows it to be used in combination with pemetrexed and platinum chemotherapy. The KEYNOTE-483 trial showed a median overall survival of 17.3 months with this combination, which is an improvement over the 16.1 months seen with chemotherapy alone.

  • 🥇 Opdivo® and Yervoy® Approval: The same year, the FDA also approved the combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab). This combination therapy has been shown to extend median overall survival to 18.1 months, as opposed to 14.1 months for chemotherapy alone.

🏥 Updated Surgical Guidelines

The National Comprehensive Cancer Network (NCCN) released new guidelines in 2026 for surgical treatment of pleural mesothelioma. They now recommend pleurectomy/decortication (P/D) as the preferred option. This shift indicates a move away from the more invasive extrapleural pneumonectomy (EPP), which is now reserved for rare cases.

💰 Treatment Costs

As of October 2026, the cost of Keytruda® averages $10,000 per 100 mg vial. The total expense will depend on dosage and insurance coverage. For the Opdivo® and Yervoy® combination, Opdivo® costs about $7,000 per 100 mg vial, while Yervoy® is approximately $1,200 per 50 mg vial.

Patients should be aware of how their insurance may affect these costs.

📅 Enrollment in Clinical Trials

For those considering clinical trials, enrollment deadlines can vary. Patients interested in participating in trials for new mesothelioma treatments should consult with healthcare providers to understand the specific timelines and eligibility criteria.

📌 Key Points Summary

  • 🩺 FDA approved Keytruda® and Opdivo® with Yervoy® for mesothelioma.
  • 🏥 NCCN recommends P/D over EPP for surgical treatment.
  • 💰 Keytruda® costs about $10,000 per vial; Opdivo® and Yervoy® are also expensive.
  • 📅 Clinical trial enrollment varies; consult healthcare providers for details.
  • 🆘 Free resources are available for support and information on treatment options.

💡 Tips for Navigating Mesothelioma Treatment Options

Review your case details with your attorney to explore your legal options regarding asbestos exposure and mesothelioma.

📝 Understand Immunotherapy Options

Immunotherapy drugs like Keytruda® and the combination of Opdivo® and Yervoy® have shown promising results. Discuss these options with your healthcare provider to see if they are suitable for your condition.

📅 Keep Track of Clinical Trials

Stay informed about ongoing clinical trials. These trials can provide access to cutting-edge therapies that may not yet be available in standard treatment protocols.

🏥 Explore Surgical Options

Consider the updated NCCN guidelines when discussing surgery with your medical team. P/D is now preferred over EPP for most patients with pleural mesothelioma.

💰 Review Treatment Costs

Discuss the costs of treatments like Keytruda® and Opdivo® with your healthcare provider and insurance company. Understanding your financial responsibilities can help you plan better.

📞 Utilize Support Resources

Reach out to organizations like the Mesothelioma Applied Research Foundation or the National Cancer Institute for resources. They offer information on treatment options and support for patients and families.

📊 Consider Multimodal Therapy

Talk to your doctor about the potential of multimodal therapy. Combining different treatment methods may improve outcomes, but recent studies suggest that surgery may not always enhance survival.

🏆 Free Options Ranked by User Reviews (2026)

No national paid service meets the review threshold for this topic. Instead, here are free government and nonprofit resources available for those affected by mesothelioma.

🥇 1. Mesothelioma Applied Research Foundation

This nonprofit organization offers a wealth of resources for mesothelioma patients. They provide support in understanding treatment options and accessing clinical trials. Their aim is to improve the quality of life for patients and fund research for better treatments.

🥈 2. National Cancer Institute (NCI)

The NCI is a government agency that provides comprehensive information on mesothelioma. They offer educational materials on treatment options, clinical trials, and support resources. Their website is a valuable tool for patients seeking detailed guides and assistance.

🥉 3. National Comprehensive Cancer Network (NCCN)

The NCCN offers clinical practice guidelines for healthcare providers. These guidelines include updated treatment options for mesothelioma, helping patients and doctors make informed decisions together.

4️⃣ American Cancer Society

The American Cancer Society provides information on cancer treatments, including mesothelioma. They offer support resources, educational materials, and guidance on navigating the healthcare system, making it easier for patients to find the help they need.

5️⃣ Cancer Support Community

The Cancer Support Community offers free emotional support and resources for cancer patients and their families. They host support groups and provide information on treatment options, ensuring that no one has to face cancer alone.

🔎 What to Check Before Paying for Help

  • 📜 Verify the organization’s credentials and mission.
  • 📞 Ask about their services and how they can assist.
  • 💬 Read reviews from other patients and families.
  • 🚫 Be cautious of any upfront fees or hidden costs.
  • 🏷️ Ensure they provide transparent information on treatment options.

❓ Frequently Asked Questions

🤔 What are the new immunotherapy treatments for mesothelioma?

Keytruda® and the combination of Opdivo® and Yervoy® are the latest FDA-approved immunotherapy options. They have shown improved median overall survival rates compared to traditional chemotherapy.

🔍 Who is eligible for Keytruda® treatment?

Patients with unresectable advanced or metastatic pleural mesothelioma who have not undergone prior systemic therapy may be eligible for Keytruda®. Eligibility is determined by the treating oncologist.

📊 How do the costs of these treatments compare?

Keytruda® averages $10,000 per vial, while Opdivo® is about $7,000 and Yervoy® around $1,200. Total costs depend on individual treatment plans and insurance coverage.

🏥 What are the surgical options for mesothelioma?

The NCCN now recommends pleurectomy/decortication over extrapleural pneumonectomy for most cases. This reflects a shift towards less invasive procedures for treating pleural mesothelioma.

📅 How can I find clinical trials for mesothelioma treatment?

Patients should consult healthcare providers to learn about ongoing clinical trials. Enrollment periods can vary, so timely conversation with medical teams is essential.

📞 What resources are available for support?

The Mesothelioma Applied Research Foundation and the National Cancer Institute offer valuable resources, support, and information for patients and families dealing with mesothelioma.

⚖️ Recent Court Rulings Related to Mesothelioma Cases

Recent court rulings have addressed issues surrounding asbestos exposure and mesothelioma claims. These rulings impact how cases are processed and the benefits available to affected individuals.

For more recent rulings, browse the more rulings on the news page.

End of October 2026 Update






 



 



Mesothelioma immunotherapy drugs are used in mesothelioma patients to bolster the patient’s immune system and force the individual’s body to attack cancerous cells. A healthy immune system is not able to fight cancerous cells because it cannot differentiate cancerous cells from normal ones. However, with the addition of immunotherapy drugs, the immune system is able to pinpoint the difference between cancer cells and health ones, thus starting the termination process of foreign bodies. 

Mesothelioma Immunotherapy Drugs


 



 



In addition to bolstering the immune system’s ability to recognize cancerous bodies, immunotherapy drugs are recommended by medical professionals in the fight against mesothelioma because they yield milder side effects than other mesothelioma treatment options, like chemotherapy. Some patients will only experience flu-like symptoms during the first cycle of immunotherapy drugs, but in general, this course of mesothelioma treatment will not impose any severe side effects. 



 



 



Immunotherapy is regarded as an alternative mesothelioma treatment. Although given this classification, immunotherapy drugs are becoming more common to fight the deadly disease. Mesothelioma immunotherapy manipulates the patient’s immune system to aid in the cancer fight. There are three different forms of immunotherapy drugs for mesothelioma treatment:



 



 



Active Immunotherapy to Treat Mesothelioma Cancer:



 



 



Active Immunotherapy treatment for mesothelioma cancer is designed to stimulate the patient’s immune system to combat the cancer. A vaccine is an example of active immunotherapy. Cancer vaccines are held separate from traditional or generic vaccines; for they are designed to combat cancerous cells that already exist in the body (traditional vaccines are administered to prevent disease). 



 



 



A mesothelioma vaccine attempts to remove cancerous cells from the mesothelioma patient. The administration of a mesothelioma vaccine is typically achieved in a laboratory by utilizing whole cancer cells or antigens extracted from infected cells. The antigens or cells are modified by doctors to be recognized by the patient’s immune system. 



Active immunotherapy treatments for mesothelioma cancer are specific treatment regimens made with cells from inside the patient’s body. 



 



 



Passive Immunotherapy Treatment for Mesothelioma Cancer:



 



 



Passive mesothelioma treatments for cancer are those which utilize components outside of the body. These types of mesothelioma treatments differ from active immunotherapy treatment methods in that the passive regiment does not attempt to force the patient’s immune system to destroy cancerous bodies. 



 



 



An example of a passive immunotherapy treatment method is monoclonal antibody therapy. Antibodies are molecules of the immune system that help fight infections and disease. In a normally-functioning immune system, antibodies are produced to recognize and adhere to foreign bodies present on foreign cells. This type of passive immunotherapy for mesothelioma cancer attempts to remove cancerous cells from a patient; the removed cells are grown in a lab with other cells that produce antibodies in response to the antigens located on the cancerous bodies. During the laboratory process, identical antibodies are produced to recognize the same antigen. 



 



 



Following this stage of passive immunotherapy for mesothelioma patients, a doctor will inject the patient with monoclonal antibodies. When entering the body, the antibodies recognize and adhere to tumor cells (the tumor cells possess a particular kind of antigen that the antibodies were synthesized to identify). If the mesothelioma treatment is successful, the patient’s immune system will recognize the antibodies and destroy the cancerous cells. As is common with active immunotherapy for mesothelioma cancer, passive treatments are specific to the individual patient because cancerous bodies from the patient’s own system are used. 



 



 



Non-Specific Immunotherapy for Mesothelioma Cancer:



 



 



Non-specific immunotherapy for mesothelioma cancer differs from the aforementioned types of immunotherapy in that they do not utilize the cancerous cells from the patient’s body. Instead, non-specific immunotherapy treatment for mesothelioma cancer is primarily based on cytokines, which are molecules of the immune system. These bodies, in essence, control and direct the patient’s immune system. Cytokines enable different types of immune cells to communicate with each other; Cytokines are typically administered in tandem with other immunotherapy treatment regiments. 



 



 



Photodynamic Mesothelioma Drugs:



 



 



Photodynamic mesothelioma therapy is a two-pronged mesothelioma treatment procedure which first uses a photosensitizing drug to make cancer cells susceptible to light. Following this, an oncologist will use light to destroy the cancerous bodies. For mesothelioma treatment,  the light (photosensitizer) used is almost always a profimer sodium beam (Photofrin), which is also applied in other cancers. 



 



 



Photodynamic therapy is currently being tested in pleural mesothelioma patients; the treatment regimen is found to improve mesothelioma survival times. This particular form of mesothelioma treatment is still undergoing tests and development for peritoneal mesothelioma cancer—doctors are still searching for an effective means to administer light to the abdominal cavity. Photodynamic mesothelioma treatment commonly yields light sensitivity side effects for roughly six weeks, which results in swelling, scarring or burning of the skin. Other side effects attached to this treatment regimen including: stomach pains, shortness of breath and persistent coughing. 



 



 



Anti-Angiogenesis Mesothelioma Drugs:



 



 



Anti-angiogenesis drugs are a new class of medications that attempt to starve cancer cells (as oppose to killing them directly). These types of mesothelioma drugs are regarded as experimental, and despite yielding a different function, may still be classified as mesothelioma chemotherapy drugs. Bevacizumab, interleukin, interferons and other types of anti-angiogenesis mesothelioma drugs prevent the body’s veins from growing towards cancerous cells. 



 



 



Anti-angiogenesis drugs target the body’s network of veins. Blood vessels provide nutrients to cancer cells; without these resources, cancer cells are unable to proliferate and divide. Mesothelioma patients who are administered anti-angiogenesis drugs will typically experience reduced side effects—the majority of problems associated with this treatment stem from the formation of new veins. Patients may also experience blood clots and excessive bleeding.